Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sellas
Biotech
Sellas’ AML asset tied to 50% response rate in certain patients
Sellas’ investigational CDK9 inhibitor has scored in a midstage AML study, demonstrating an ORR of more than double the 20% goal.
Gabrielle Masson
Jul 15, 2025 10:34am
Sellas mulling ‘strategic options’ to stay afloat, including sale
Feb 27, 2019 10:13am
Sellas snags Nasdaq listing in reverse merger with Galena
Aug 8, 2017 9:05am
Advaxis pens backloaded $358M cancer delivery tech deal
Feb 27, 2017 8:43am
